Clinical Monograph: Elvanse 30 mg (Lisdexamfetamine Dimesylate)

1. Classification and Chemical Overview

Lisdexamfetamine dimesylate is a pharmacologically inactive prodrug composed of dextroamphetamine covalently bonded to the essential amino acid L-lysine. Chemically designated as $(2S)$-2,6-diamino-N-[(1S)-1-methyl-2-phenylethyl]hexanamide dimethanesulfonate. Under the Anatomical Therapeutic Chemical (ATC) system, lisdexamfetamine is indexed under N06BA12.

• Product Context: Elvanse 30 mg represents a standard starting therapeutic strength for initiating treatment in pediatric and adult patients.

• Controlled Status: Strictly regulated as a Prescription Only Medicine (POM) and a Schedule II Controlled Substance (or Class B / Schedule 2 Controlled Drug internationally) due to its high potential for abuse, psychological dependence, and misuse.

2. Mechanism of Action and Pharmacodynamics

Elvanse functions as a prodrug designed to deliver sustained, smooth systemic exposure to active dextroamphetamine:

• Enzymatic Bioactivation: Following oral ingestion, the intact molecule is absorbed into the bloodstream where red blood cell-associated enzymes hydrolyze the amide bond, cleaving the L-lysine molecule and releasing active dextroamphetamine.

• Presynaptic Monoamine Release: Dextroamphetamine enters presynaptic nerve terminals via monoamine transporters, reversing transporter direction and inducing the robust release of dopamine (DA) and norepinephrine (NE) into the synaptic cleft.

• Clinical Pharmacodynamics: Sustained catecholamine transmission improves executive function, attention span, and impulse control in ADHD, while modulating neural pathways involved in binge eating behaviors.

3. Approved Clinical Indications and Dosing Scope

Licensing for Elvanse includes:

• Attention Deficit Hyperactivity Disorder (ADHD): Treatment of ADHD in children aged 6 years and older and adults as part of a total comprehensive management program.

• Binge Eating Disorder (BED): Moderate to severe binge eating disorder in adults.

Dosing & Administration Regimen:

• Morning Administration: Taken orally once daily in the morning. Avoid afternoon or evening administration due to the high risk of severe, prolonged insomnia.

• Starting Strength & Titration: The 30 mg capsule serves as the standard recommended starting dose for both ADHD and BED. Dosage can be titrated upward at weekly intervals based on clinical response and tolerability.

• Capsule Integrity: Capsules can be swallowed whole or opened and the entire contents mixed into soft food (such as yogurt) or liquids (water or orange juice) for immediate consumption. Do not crush, divide, or chew capsule contents.

4. Pharmacokinetic Profile and Metabolic Fate

• Absorption: Rapidly and completely absorbed from the gastrointestinal tract following oral administration. Peak plasma concentrations of active dextroamphetamine are achieved within 3 to 4 hours post-dose.

• Distribution: Readily crosses the blood-brain barrier and distributes widely across body tissues. Plasma protein binding of dextroamphetamine is low (~15% to 20%).

• Biotransformation: Converted primarily in blood via enzymatic hydrolysis into active dextroamphetamine and inactive L-lysine. Subsequent metabolism of dextroamphetamine occurs in the liver via aromatic and aliphatic hydroxylation.

• Elimination: Excreted predominantly via the kidneys in urine as unchanged amphetamine and metabolites. Urinary elimination is heavily influenced by urinary pH; acidic urine accelerates renal clearance, whereas alkaline urine prolongs elimination half-life. The terminal elimination half-life of dextroamphetamine averages 10 to 12 hours.

5. Physiological Effects and Adverse Event Spectrum

Elvanse stimulates the sympathetic nervous system, accelerates heart rate, increases blood pressure, and suppresses appetite.

Adverse Drug Reaction Spectrum

• Very Common ($\ge 1/10$): Decreased appetite, insomnia, dry mouth, upper abdominal pain, weight loss, headache, irritability, nausea.

• Common ($\ge 1/100$ to $<1/10$): Tachycardia, palpitations, anxiety, dizziness, restlessness, diarrhea, constipation, hyperhidrosis, bruxism, nasopharyngitis.

• Uncommon ($\ge 1/1,000$ to $<1/100$): Hypertension, dysgeusia, tremor, blurred vision, rash, libido changes, emotional lability.

• Rare / Severe (<1/1,000): Psychotic episodes, hallucinations, cardiomyopathy (with chronic high-dose misuse), seizures, cerebrovascular accidents, myocardial infarction, sudden cardiac death in vulnerable individuals.

6. Contraindications, Drug Interactions, and Clinical Precautions

Contraindications

• Known hypersensitivity to amphetamine products or formulation excipients.

• Concomitant use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of their cessation (risk of life-threatening hypertensive crisis).

• Advanced arteriosclerosis, symptomatic cardiovascular disease, moderate-to-severe hypertension, or structural cardiac abnormalities.

• Hyperthyroidism or glaucoma.

• History of active drug abuse or substance use disorder.

Key Drug Interactions

• Monoamine Oxidase Inhibitors (MAOIs): Concurrent administration triggers severe hypertensive crises and dangerous hyperthermia.

• Serotonergic Agents (SSRIs, SNRIs): Co-administration elevates the risk of serotonin syndrome.

• Acidifying & Alkalinizing Agents: Gastrointestinal and urinary acidifiers accelerate clearance and reduce efficacy, whereas urinary alkalinizers prolong half-life and increase systemic exposure.

• Antihypertensives: Stimulants can antagonize the blood pressure-lowering effects of antihypertensive medications.

Clinical Precautions and Monitoring

• Boxed Warning (Abuse, Misuse, and Dependence): CNS stimulants have a high potential for abuse and dependence. Assess clinical risk prior to prescribing and monitor patients regularly for signs of misuse, diversion, or dose escalation.

• Cardiovascular Evaluation: Evaluate cardiac status prior to treatment. Monitor blood pressure and heart rate regularly during therapy, particularly in patients with underlying cardiovascular conditions.

• Growth Suppression: Long-term stimulant use in pediatric patients can be associated with temporary suppression of weight gain and linear growth velocity; monitor height and weight periodically.